On September 19, 2022 The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") reported its earnings guidance for the current fiscal year 2022 due to currency gains and efficiencies in study initiation costs. The currency translation gains are due to good currency management in connection with the positive development of the U.S. dollar. The initial set-up costs for the prospective FDA pivotal study for Epi proColon "Next-Gen", for which the first subject was recently enrolled, were lower than anticipated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For the full year 2022, the Executive Board now expects adjusted EBITDA (before share-based payment expenses) to be within the range of EUR -10.5 million to EUR -11.5 million and cash consumption in the range of EUR -14.5 million to EUR -15.5 million. Previously, the Company expected EBITDA (before share-based payment expenses) and cash consumption to range from EUR -15.0 million to EUR -17.0 million. The revenue forecast remains unchanged between EUR 0.3 million to EUR 0.8 million.